DOI:

Tryton Side-Branch Stent

Aaron V. Kaplan1,2*, M.D; H. Richard Davis2

Description

The Tryton Side-Branch Stent™ is a slotted tube balloon deployable stent with a modular design comprise of three zones: Distal (Side-Branch) Zone, Central (Transition) Zone and Proximal (Main Vessel) Zone (Figure 1).

Figure 1. Schematic representing the Tryton Side-Branch Stent showing three zones: Distal (Side-Branch) Zone, Central (Transition) Zone and Proximal (Main Vessel) Zone. When positioned correctly within the vasculture the Side-Branch Zone resides in the side-branch, Transition Zone at the side-branch origin and the Main Vessel Zone in the main vessel proximal to the side-branch origin.

Tryton performs like a standard high-performance workhorse stent, i.e., balloon expandable, tracking over a single wire and axially oriented without the need for rotational orientation. The Tryton is simply tracked over a guidewire placed in the side-branch, such that the transition zone is at the side-branch origin. To insure precise delivery, the Tryton Side-Branch Stent is mounted on a balloon with four shaft markers, 2 standard proximal/distal stent markers, and 2 additional markers delineating the Transition Zone. The Tryton Stent is deployed after which the guidewire initially placed in the side-branch is repositioned into the distal main vessel. The Tryton stent is compatible with any standard workhorse stent (bare metal or DES), which is tracked into the Main Vessel Zone of the Tryton Stent and between specially designed fronds exiting into the distal main vessel stent (Figure 2).

Figure 2. Schematic representing the spacial relationship between the Tryton Side-Branch Stent (deployed) with an undeployed main vessel stent. The distal end of the main vessel stent has been tracked through the proximal Main Vessel Zone of the Tryton Stent, between the specially designed fronds and into the distal main vessel.

The main vessel stent is deployed after which a kissing balloon inflation is performed. Employing this strategy provides a means to definitively treat bifurcation lesions with similar coverage and hoop strength currently available with state of the art stents used in straight lesions (Figure 3).

Figure 3. Photograph of a Tryton Side-Branch Stent deployed in a plexiglass model in combination with a Cypher Stent (Cordis/ Johnson&Johnson, Miami, FL) using the protocol outlined within main text.

History

Tryton Medical, Inc. is a privately held company with offices in Newton, Massachusetts, USA founded to develop devices to treat bifurcation lesions within the coronary, cerebral and peripheral circulations.

Volume 2 Number 2
Aug 20, 2006
Volume 2 Number 2
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00601 Jun 15, 2026
Unloading the clock: when timing meets physiology in STEMI shock
Møller J and Schrage B
free

Editorial

10.4244/EIJ-D-26-00394 Jun 15, 2026
Transcatheter edge-to-edge repair for primary mitral regurgitation: what lies ahead?
Petronio A and Mazzola M
free

Original Research

10.4244/EIJ-D-25-01308 Jun 15, 2026
Temporal trends in mitral edge-to-edge repair for primary mitral regurgitation
Koell B et al

Flashlight

10.4244/EIJ-D-25-01353 Jun 15, 2026
Transcatheter approximation of papillary muscles
Tekieli L et al
open access

Editorial

10.4244/EIJ-D-26-00479 Jun 1, 2026
Valve thrombosis or valve deterioration: what truly drives the prognosis?
Waksman R and Phichaphop A
free
Trending articles
202.75

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
35.3

Original Research

10.4244/EIJ-D-25-01006 Mar 16, 2026
Clinical outcomes and haemodynamic response after blinded stress assessment of moderate aortic stenosis
Eerdekens R et al
32.2

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
27.1

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
27.1

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved